Dr Reddy's Lab launches Bortezomib for Injection in US market

28 Jul 2022 , 09:17 AM

Dr. Reddy’s Laboratories Ltd has announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).

According to IQVIA Health, the Velcade Brand and generic had U.S. sales of ~$1.2 billion MAT for the most recent 12 months ending in May 2022.

Further, Dr. Reddy’s Bortezomib for Injection is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use, the company said.

At around 9:17 AM, Dr Reddys Laboratories was trading at Rs4,254.40 per share down by Rs30.95 or 0.72% from its previous closing of Rs4,285.35 per share on the BSE.